Independent and interactive contributions of white matter hyperintensities and Alzheimer’s disease imaging and plasma biomarkers to cognitive decline in older adults without dementia
Dario Bachmann·Anton Gietl·Antje Saake·Sandro Studer·Esmeralda Gruber·Andreas Buchmann·Martin Hüllner·Kaj Blennow·Henrik Zetterberg·Roger M. Nitsch·Christoph Höck·Valérie Treyer·Christoph Gericke·Katrin Rauen·Maha Wybitul
Accounting for common co-pathologies such as white matter hyperintensities (WMH) may improve the prognostic performance of imaging and blood-based biomarkers for cognitive decline in Alzheimer’s disease (AD). Plasma biomarkers including p-tau217, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) as well as imaging biomarkers including hippocampus volume, amyloid-β (Aβ) PET, and WMH have been reported to be associated with decline across multiple cognitive domains. Howev